BON CHARGE Unveils First-Ever Global Red Light Therapy Trend Report
22.1.2025 10:00:00 EET | Business Wire | Press release
BON CHARGE, a global leader in premium wellness technology, today announces the release of its inaugural Global Red Light Therapy Trend Report, showcasing how red light therapy is fast becoming a cornerstone of modern wellness routines. Based on a global survey of 7,000 adults across the U.S., UK, UAE, and Australia, the report highlights the rising adoption of red light therapy, particularly among younger consumers, with the UAE leading with seven in ten adults actively using red light therapy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122177591/en/
BON CHARGE Unveils First-Ever Global Red Light Therapy Trend Report (Photo: Business Wire)
Coinciding with the release, BON CHARGE debuts its brand refresh, including a redesigned website. This emphasizes BON CHARGE’s mission to simplify wellness by offering the world’s widest range of wellness products on a single, easy-to-access platform, empowering individuals to prioritize their self-care with science-backed technology solutions.
“As consumers become increasingly interested in their overall wellness, they are searching for accessible tools that offer multiple benefits, making red light therapy a game-changer,” said Katie Mant, Co-Founder of BON CHARGE. “Our research underscores its impact on key areas like skin appearance, sleep, and recovery, showcasing its role in shaping the future of proactive wellness worldwide.”
Red Light Therapy: A Global Trend in Wellness
The BON CHARGE Global Red Light Therapy Trend Report provides key insights into how this emerging technology is reshaping global wellness routines:
- UAE Leading the Way: Red light therapy has gained remarkable traction in the UAE, where 70% of adults report using it—far exceeding adoption rates in other markets. Nearly a third (30%) use it monthly, underscoring its popularity as a regular wellness practice.
- Younger Generations Drive Adoption: Across all surveyed markets, adults aged 18-34 are the most engaged users of red light therapy, with standout adoption rates of 77% in the UAE, 53% in the U.S. and Australia, and 46% in the UK.
- A Recent Addition to Wellness Routines: Red light therapy is still a relatively new addition for many users, with two-thirds globally reporting they started in the past two years. Younger adults (18-34) are driving this trend, with 73% of users in the UK, 70% in the UAE and 71% in the U.S. and Australia having adopted the practice recently.
- Top Device of Choice: Red light face masks lead globally as the most popular device, chosen by around a third of users (35% in the UAE, 34% in Australia, 36% in the UK and 27% in the U.S.). Note: Preferences vary by region with devices to soothe joint stiffness taking the lead in the UK and U.S. (38% and 30%, respectively).
Regional Insights Reflect Diverse Motivations
Red light therapy is a growing phenomenon. While muscle and joint relaxation is the top reason for use globally, regional nuances reveal additional motivations behind its widespread appeal:
- United Arab Emirates: The UAE sets the pace for global adoption with nearly 70% of adults engaged with red light therapy. A greater understanding of red light therapy and professional endorsements drive this trend, with 37% of users recommended by a skin specialist.
- Australia: Australians cite sleep improvement and skincare benefits as key reasons for use, after muscle and joint relaxation, and well over half (61%) have adopted red light therapy within the past two years.
- United States: Adoption is stronger among men than women in the United States, with nearly 40% reporting usage. Improved sleep and mood are cited as key motivators (28% and 24%, respectively) by users, highlighting the growing focus on recovery and mental well-being.
- United Kingdom: While adoption lags behind other markets, red light therapy is rapidly gaining traction among younger adults, with 73% of users aged 18-34 starting in the last two years. With lead motivation for use being skincare benefits, following muscle and joint relaxation.
“This report reflects a global movement toward proactive wellness,” said Andy Mant, Co-Founder of BON CHARGE. “Red light therapy’s rapid adoption, particularly among younger generations, signals a significant shift. As science continues to validate its benefits, we believe it will become as essential to wellness as nutrition and fitness.”
Explore the Full Report and Press Kit
Access the BON CHARGE Global Red Light Therapy Global Trend Report and explore key findings, visual assets, and additional resources in our digital press kit. Visit boncharge.com to download the report and learn more about BON CHARGE’s pioneering wellness solutions.
Notes to Editors
Research of 7,000 adults across the UK, USA, UAE, and Australia by Opinium Research in December 2024.
About BON CHARGE
Founded in 2017 by Katie and Andy Mant, BON CHARGE is setting new standards in simplifying wellness by offering the widest range of science-backed technology solutions to help individuals navigate their wellness journeys. The brand celebrates wellness as a continuous journey, honoring individuality and inspiring growth through community and shared knowledge. From sleep and recovery to beauty and mental well-being, BON CHARGE is a trusted partner in proactive self-care. Headquartered in Perth, Australia, every product is rooted in rigorous scientific research and designed to help individuals in achieving their wellness goals. For more information, visit boncharge.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122177591/en/
Contacts
Press Contact
Jack Taylor PR
boncharge@jacktaylorpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom